Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation

Blood

Volumn 103, Issue 3, 2004, Pages 1158-1165

  Godfrey, Wayne R ^a   Krampf, Mark R ^a   Taylor, Patricia A ^a   Blazar, Bruce R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANDIDA ANTIGEN; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; VIRUS ANTIGEN;

ADOPTIVE TRANSFER; ALLOIMMUNITY; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL SELECTION; CELL STIMULATION; CONTROLLED STUDY; DENDRITIC CELL; DYE DILUTION CURVE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HLA TYPING; HUMAN; IMMUNOREACTIVITY; IN VIVO STUDY; LYMPHOCYTE DEPLETION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

EID: 1642541111     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-04-1098     Document Type: Article

References (38)

1. Martelli MF, Aversa F, Bachar-Lustig E, et al. Transplants across human leukocyte antigen barriers. Semin Hematol. 2002;39:48-56.
2. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92:3515-3520.
3. Blazar BR, Korngold R, Vallera DA. Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev. 1997;157:79-109.
4. Teshima T, Ferrara JL. Understanding the alloresponse: new approaches to graft-versus-host disease prevention. Semin Hematol. 2002;39:15-22.
5. Cavazzana-Calvo M, Andre-Schmutz I, Hacein-Bey-Abina S, Bensoussan D, Le Deist F, Fischer A. Improving immune reconstitution while preventing graft-versus-host disease in allogeneic stem cell transplantation. Semin Hematol. 2002;39:32-40.
6. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001;98:3192-3204.
7. Wagner JE, Thompson JS, Carter S, Jensen L, Kernan NA. Impact of graft-versus-host disease (GVHD) prophylaxis on 3-year disease-free survival (DFS): results of a multi-center, randomized phase II-III trial comparing T-cell depletion/cyclosporine (TCD) and methotrexate/cyclosporine (M/C) in 410 recipients of unrelated donor bone marrow (BM) [abstract]. Blood. 2002;100:274a.
8. Cavazzana-Calvo M, Fromont C, Le Deist F, et al. Specific elimination of alloreactive T-cells by an anti-interieukin-2 receptor B chain-specific immunotoxin. Transplantation. 1990;50:1-7.
9. Mavroudis DA, Dermime S, Molldrem J, et al. Specific depletion of alloreactive T-celis in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions. Br J Haematol. 1998;101:565-570.
10. Montagna D, Yvon E, Calcaterra V, et al. Depletion of alloreactive T-celis by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood. 1999;93:3550-3557.
11. Garderet L, Snell V, Przepiorka D, et al. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation. 1999;67:124-130.
12. Koh MB, Prentice HG, Lowdell MW. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis. Bone Marrow Transplant. 1999;23:1071-1079.
13. van Dijk AM, Kessler FL, Stadhouders-Keet SA, Verdonck LF, de Gast GC, Otten HG. Selective depletion of major and minor histocompatibility antigen reactive T-cells: towards prevention of acute graft-versus-host disease. Br J Haematol. 1999;107:169-175.
14. Fehse B, Frerk O, Goldmann M, Bulduk M, Zander AR. Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69). Br J Haematol. 2000;109:644-651.
15. Rencher SD, Houston, JA, Lockey TD, Hurwitz JL. Eliminating graft-versus-host potential from T-cell immunotherapeutic populations. Bone Marrow Transplant. 1996;18:415-420.
16. Hartwig UF, Robbers M, Wickenhauser C, Huber C. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. Blood. 2002;99:3041-3049.
17. Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T-cells by photodynamic cell purging process. Blood. 2002;99:3083-3088.
18. + T-cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci U S A. 2003;100:1180-1184.
19. Cavazzana-Calvo M, Stephan JL, Sarnacki S, et al. Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T-cells in an H-2 haplotype disparate mouse combination. Blood. 1994;83:288-298.
20. Koh MB, Prentice HG, Corbo M, Morgan M, Cotter FE, Lowdell MW. Alloantigen-specific T-cell depletion in a major histocompatibility complex fully mismatched murine model provides effective graft-versus-host disease prophylaxis in the presence of lymphoid engraftment. Br J Haematol. 2002;118:108-116.
21. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet. 2002;360:130-137.
22. Lyons AB. Analysing cell division in vivo and in vitro using flow cytometdc measurement of CFSE dye dilution. J Immunol Methods. 2000;243:147-154.
23. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T-cells in vivo: new answers to an old question. J Immunol. 2001;166:973-981.
24. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109-1118.
25. Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods. 1999;223:1-15.
26. Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A. Maturation, activation, and protection of denddtic cells induced by double-stranded RNA. J Exp Med. 1999;189:821-829.
27. Spisek R, Bretaudeau L, Barbieux L, Meflah K, Gregoire M. Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother. 2001;50:417-427.
28. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413:732-738.
29. Visintin A, Mazzoni A, Spitzer JH, Wyllie DH, Dower SK, Segal DM. Regulation of Toll-like receptors in human monocytes and dendritic cells. J Immunol. 2001;166:249-255.
30. Russell CA, Brondsted L, Vindelov LL. Design of limiting dilution analysis experiments for helper T lymphocyte precursor frequency determination in the context of allogeneic bone marrow transplantation. J Immunol Methods. 1999;225:113-124.
31. Blazar BR, Taylor PA, Noelle RJ, Vallera DA. CD4(+) T-cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. J Clin Invest. 1998;102:473-482.
32. Chang CH, Hong SC, Hughes CC, Janeway CA Jr, Flavell RA. CIITA activates the expression of MHC class II genes in mouse T cells. Int Immunol. 1995;7:1515-1518.
33. Often LA, Tacchini-Cottier F, Lohoff M, et al. Deregulated MHC class II transactivator expression leads to a strong Th2 bias in CD4+ T lymphocytes. J Immunol. 2003;170:1150-1157.
34. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811.
35. Amrolia PJ, Muccioli-Casadei G, Yvon E, et al. Selective depletion of donor allo-reactive T-cells without loss of anti-viral or anti-leukemic responses. Blood. 2003;102:2292-2299.
36. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T-cells in the antitumor immune response. J Exp Med. 1998;188:2357-2368.
37. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, Van Lier RA, Ten Berge IJ. Primary immune responses to human CMV: a critical role IFN-gamma-producing CD4+ T-cells in protection against CMV disease. Blood. 2003;101:2686-2692.
38. O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev. 1997;157:195-216.